Department of Neurology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210008, China; Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China; Department of Neurology, Nanjing Drum Tower Hospital, State Key Laboratory of Pharmaceutical Biotechnology and Institute of Translational Medicine for Brain Critical Diseases, Nanjing University, Nanjing, 210008, China.
Neurochem Int. 2024 May;175:105676. doi: 10.1016/j.neuint.2024.105676. Epub 2024 Feb 7.
Microglia-mediated neuroinflammation is the major contributor to the secondary brain injury of ischemic stroke. NLRP3 is one of the major components of ischemia-induced microglial activation. Echinatin, a chalcone found in licorice, was reported to have the activity of anti-inflammation and antioxidant. However, the relative study of echinatin in microglia or ischemic stroke is still unclear.
We intravenously injected echinatin or vehicle into adult ischemic male C57/BL6J mice induced by 60-min transient middle cerebral artery occlusion (tMCAO). The intraperitoneal injection was performed 4.5 h after reperfusion and then daily for 2 more days. Infarct size, blood brain barrier (BBB) leakage, neurobehavioral tests, and microglial-mediated inflammatory reaction were examined to assess the outcomes of echinatin treatment. LPS and LPS/ATP stimulation on primary microglia were used to explore the underlying anti-inflammatory mechanism of echinatin.
Echinatin treatment efficiently decreased the infarct size, alleviated blood brain barrier (BBB) damage, suppressed microglial activation, reduced the production of inflammatory factors (e.g., IL-1β, IL-6, IL-18, TNF-α, iNOS, COX2), and relieved post-stroke neurological defects in tMCAO mice. Mechanistically, we found that echinatin could suppress the NLRP3 assembly and reduce the production of inflammatory mediators independently of NF-κB and monoamine oxidase (MAO).
Based on our study, we have identified echinatin as a promising therapeutic strategy for the treatment of ischemic stroke.
小胶质细胞介导的神经炎症是缺血性中风继发性脑损伤的主要原因。NLRP3 是缺血诱导小胶质细胞活化的主要成分之一。甘草中的查尔酮化合物,当药黄素,具有抗炎和抗氧化作用。然而,当药黄素在小胶质细胞或缺血性中风中的相关研究尚不清楚。
我们通过 60 分钟短暂性大脑中动脉闭塞(tMCAO)诱导成年雄性 C57/BL6J 缺血性中风模型,然后尾静脉注射当药黄素或载体。再灌注后 4.5 小时进行腹腔注射,然后每天再注射 2 天。通过梗死面积、血脑屏障(BBB)渗漏、神经行为学测试和小胶质细胞介导的炎症反应评估当药黄素治疗的效果。通过 LPS 和 LPS/ATP 刺激原代小胶质细胞来探索当药黄素的抗炎作用机制。
当药黄素治疗能有效减小梗死面积,减轻血脑屏障(BBB)损伤,抑制小胶质细胞活化,减少炎症因子(如 IL-1β、IL-6、IL-18、TNF-α、iNOS、COX2)的产生,并缓解 tMCAO 小鼠中风后的神经功能缺损。在机制上,我们发现当药黄素可以抑制 NLRP3 组装,并减少炎症介质的产生,这一作用不依赖 NF-κB 和单胺氧化酶(MAO)。
基于我们的研究,我们已经确定当药黄素是治疗缺血性中风的一种有前途的治疗策略。